Adaptive Biotechnologies Q2 2024 GAAP EPS $(0.31) Beats $(0.33) Estimate, Sales $43.190M Beat $38.664M Estimate
Portfolio Pulse from Benzinga Newsdesk
Adaptive Biotechnologies (NASDAQ:ADPT) reported Q2 2024 GAAP EPS of $(0.31), beating the estimate of $(0.33). Sales were $43.190M, surpassing the $38.664M estimate but down 11.72% from last year's $48.926M.
August 01, 2024 | 8:51 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Adaptive Biotechnologies reported better-than-expected Q2 2024 GAAP EPS of $(0.31) and sales of $43.190M, beating estimates but showing a year-over-year decline in revenue.
The better-than-expected EPS and sales figures are positive indicators for the stock in the short term, despite the year-over-year decline in revenue. Investors may react positively to the earnings beat.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100